中華銀科技 (00515.HK)擬溢價81.82%配售2.72億股 淨籌約2700萬港元
格隆匯4月25日丨中華銀科技 (00515.HK)宣佈,於2022年4月25日,公司擬向認購人(陳小江、梁堅妹及蔡非)配發合計2.72億股新股,佔經擴大後公司股份約8.12%。每股配售價為0.10港元,較4月25日收市價溢價約81.82%。
認購事項的所得款項總額及淨額預期分別約為2720萬港元及2700萬港元。公司擬將認購事項所得款項淨額中的2300萬港元用於廠房的建設成本及償還集團到期時的債務及負債,及400萬港元用作集團的營運資金(例如薪金、租金付款、專業費用及辦公室開支)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.